Brief: Trevi Therapeutics Reports Positive Results From The Ph2b/3 Prism Trial Of Haduvio In The Treatment Of Prurigo Nodularis

Trevi Therapeutics

29/06/2022 12:31

June 29 (Reuters) - Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS REPORTS POSITIVE RESULTS FROM THE
PH2B/3
PRISM TRIAL OF HADUVIO™ IN THE TREATMENT OF PRURIGO NODULARIS
    * TREVI THERAPEUTICS INC - TRIAL ALSO MET KEY SECONDARY
ENDPOINTS,
WITH A SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES
    * TREVI THERAPEUTICS INC - HADUVIO (ORAL NALBUPHINE ER)
DEMONSTRATED STATISTICALLY SIGNIFICANT RESULTS ON PRIMARY
EFFICACY ENDPOINT
    * TREVI THERAPEUTICS INC - SAFETY RESULTS OF TRIAL WERE
GENERALLY
CONSISTENT WITH KNOWN SAFETY PROFILE OF HADUVIO FROM PREVIOUS
TRIALS
    * TREVI THERAPEUTICS INC - ADVERSE EVENTS MOST COMMONLY
OBSERVED
WITH HADUVIO WERE NAUSEA, DIZZINESS, HEADACHE, AND CONSTIPATION

Source text for Eikon:  ID:nPn4czHfna 
Further company coverage:  TRVI.O 

 ((Reuters.Briefs@thomsonreuters.com;))